A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) / G. Curigliano, S. Loibl, V. Müller, X. Pivot, A. Wardley, D. Cameron. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 27:Suppl. 6(2016 Oct 01). ((Intervento presentato al 41. convegno ESMO Congress : October, 7th - 11th tenutosi a Copenhagen nel 2016 [10.1093/annonc/mdw365.91].

A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC)

G. Curigliano;
2016

Settore MED/06 - Oncologia Medica
1-ott-2016
European Society for Medical Oncology
Article (author)
File in questo prodotto:
File Dimensione Formato  
AnnalsOncology_BreastCancer_2016.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 67.01 kB
Formato Adobe PDF
67.01 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/553264
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact